<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469013</url>
  </required_header>
  <id_info>
    <org_study_id>14116</org_study_id>
    <secondary_id>I4V-JE-JADN</secondary_id>
    <nct_id>NCT01469013</nct_id>
  </id_info>
  <brief_title>Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of Baricitinib (LY3009104) in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension),
      placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese
      participants with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy.
      Baricitinib will be orally administered once a day with background methotrexate [6 to 16
      milligrams (mg)/week] therapy for 12 weeks in the double-blind treatment period (1, 2, 4 or 8
      mg/day, or placebo), and for 52 weeks in the single-blind extension period (4 or 8 mg/day).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .</measure>
    <time_frame>12 weeks</time_frame>
    <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) * 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</measure>
    <time_frame>Baseline, 64 weeks</time_frame>
    <description>DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in SDAI Responses up to 64 Weeks (Part B)</measure>
    <time_frame>Baseline, 64 weeks</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)</measure>
    <time_frame>Baseline, 64 weeks</time_frame>
    <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of ACR-N Response (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of ACR-N Response (Part B)</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)</measure>
    <time_frame>Baseline up to 64 weeks</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</measure>
    <time_frame>Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.</time_frame>
    <description>Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</measure>
    <time_frame>Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>4-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <arm_group_label>8-mg Baricitinib (LY3009104)</arm_group_label>
    <other_name>JAK1/JAK2 inhibitor</other_name>
    <other_name>JAK1 inhibitor</other_name>
    <other_name>JAK2 inhibitor</other_name>
    <other_name>NCB028050</other_name>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <arm_group_label>4-mg Baricitinib (LY3009104)</arm_group_label>
    <other_name>JAK1/JAK2 inhibitor</other_name>
    <other_name>JAK1 inhibitor</other_name>
    <other_name>JAK2 inhibitor</other_name>
    <other_name>NCB028050</other_name>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <arm_group_label>1-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>2-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>4-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>8-mg Baricitinib (LY3009104)</arm_group_label>
    <other_name>JAK1/JAK2 inhibitor</other_name>
    <other_name>JAK1 inhibitor</other_name>
    <other_name>JAK2 inhibitor</other_name>
    <other_name>NCB028050</other_name>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered orally as background therapy</description>
    <arm_group_label>1-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>2-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>4-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>8-mg Baricitinib (LY3009104)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory males or females between the ages of 20 and 75 years, inclusive, at time of
             study entry

          -  Diagnosis of adult-onset RA (of at least 6 months duration but not longer than 15
             years prior to screening) according to the 2010 American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) Responder Index classification
             criteria for RA

          -  Have active RA defined as at least 6 swollen and at least 6 tender joints based on the
             66/68 joint count

          -  Regular use of MTX for at least 12 weeks, and treatment at a stable dose of 6 to 16
             mg/week (2 or 3 times a week) for at least 8 weeks prior to the treatment period. The
             dose of MTX should remain stable throughout the study, but may be adjusted for safety
             reasons.

          -  For participants receiving corticosteroids, they must be on a dose not to exceed 10 mg
             of prednisone daily (or equivalent) and have been on the same dosing regimen for at
             least 6 weeks prior to the treatment period

          -  Have C-Reactive Protein (CRP) measurement &gt; 0.5 milligrams/deciliter (mg/dL) or
             Erythrocyte Sedimentation Rate (ESR) &gt; 28 millimeters/hour (mm/hr). The CRP and ESR
             may be repeated once during the screening period at the discretion of the
             investigator, and the repeat results may be accepted for study eligibility purposes

        Exclusion Criteria:

          -  Use of nonsteroidal anti-inflammatories (NSAIDs) for less than 4 weeks prior to the
             treatment period. If on NSAIDs, must be on a stable dose of the drug for at least 4
             weeks prior to the treatment period and must remain on a stable dose throughout the
             study

          -  Received prior treatment with an oral Janus Kinase (JAK) inhibitor regardless of when
             they received it

          -  Have a diagnosis of Felty's syndrome

          -  Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV
             antibodies

          -  Have hepatitis C virus (HCV; positive for anti-hepatitis C antibody with confirmed
             presence of HCV)

          -  Positive for hepatitis B surface antigen (HBsAg+), OR negative for hepatitis B surface
             antigen (HBsAg-), but positive for hepatitis B core antibody (HBcAb+) and/or positive
             for hepatitis B surface antibody (HBsAb+) with positive Hepatitis B virus
             (HBV)-deoxyribonucleic acid (DNA) [≥2.1 Log copy/mL by Polymerase Chain Reaction (PCR)
             method] detected in the serum

          -  Have a positive result of the QuantiFERON®-tuberculosis (TB) Gold test (QFT-G) or a
             purified protein derivative (PPD) test

          -  Have estimated Glomerular Filtration Rate (GFR) from serum creatinine using the
             Modification of Diet in Renal Disease (MDRD) method of &lt;50 milliliter/minute (mL/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaragi</city>
        <zip>316-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>857-1165</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oita</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>700-8607</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toyama</city>
        <zip>933-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>February 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <disposition_first_submitted>January 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 21, 2013</disposition_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants on background methotrexate therapy were assigned to a dose of 1, 2, 4, 8 mg baricitinib (LY3009104) or placebo capsule once daily in a double blind manner for 12 weeks followed by single blind treatment of 4 mg or 8 mg baricitinib (LY3009104) tablet once daily for 52 weeks extension period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: 1 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Part A: 2 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Part A: 4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Part A: 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Part A: Placebo</title>
          <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Part:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 1 x 1-mg LY3009104 capsule +1 identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg LY3009104 and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P7">
          <title>Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30</title>
          <description>Participants on background methotrexate therapy who were administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P8">
          <title>Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30</title>
          <description>Participants on background methotrexate therapy who were administered 1 x 4-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P9">
          <title>Part B: Placebo /4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 2 placebo capsules orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P10">
          <title>Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30</title>
          <description>Participants on background methotrexate therapy who were administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P11">
          <title>Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300</title>
          <description>Participants on background methotrexate therapy who were administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P12">
          <title>Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30</title>
          <description>Participants on background methotrexate therapy who were administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="P13">
          <title>Part B: Placebo / 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 2 placebo capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Treatment Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Extension Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="24"/>
                <participants group_id="P10" count="11"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="24"/>
                <participants group_id="P13" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="24"/>
                <participants group_id="P10" count="11"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="24"/>
                <participants group_id="P13" count="23">1 participant discontinued prior to receiving study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="18"/>
                <participants group_id="P13" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received any amount of study treatment. All participants who completed Part A were re-randomized to 4 mg or 8 mg in Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: 1 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy were administered 1 mg baricitinib (LY3009104) orally once daily for 12 weeks in Part A and received 4 mg or 8 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="B2">
          <title>Part A: 2 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy were administered 2 mg baricitinib (LY3009104) orally once daily for 12 weeks in Part A and received 4 mg or 8 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="B3">
          <title>Part A: 4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy were administered 4 mg baricitinib (LY3009104) orally once daily for 12 weeks in Part A and received 4 mg or 8 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="B4">
          <title>Part A: 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy were administered 8 mg baricitinib (LY3009104) orally once daily for 12 weeks in Part A and received 4 mg or 8 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="B5">
          <title>Part A: Placebo</title>
          <description>Participants on background methotrexate therapy were administered placebo orally once daily for 12 weeks in Part A and received 4 mg or 8 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="49"/>
            <count group_id="B6" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="12.8"/>
                    <measurement group_id="B2" value="56.1" spread="11.5"/>
                    <measurement group_id="B3" value="57.5" spread="10.4"/>
                    <measurement group_id="B4" value="53.6" spread="11.3"/>
                    <measurement group_id="B5" value="51.1" spread="12.0"/>
                    <measurement group_id="B6" value="53.6" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .</title>
        <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) * 100.</description>
        <time_frame>12 weeks</time_frame>
        <population>All participants who received at least 1 dose of 4 mg, 8 mg baricitinib (LY3009104) or placebo in Part A as per protocol for combined analysis .</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Combined 4 mg and 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1- 4 mg baricitinib (LY3009104) capsule +1 identical placebo capsule or 2 x 4-mg baricitinib (LY3009104) capsules, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .</title>
          <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) * 100.</description>
          <population>All participants who received at least 1 dose of 4 mg, 8 mg baricitinib (LY3009104) or placebo in Part A as per protocol for combined analysis .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks</title>
        <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104) (Part B)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104) (Part B)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsule or placebo capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks</title>
          <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
          <population>All participants who received any amount of study drug in Part B.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)</title>
        <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) * 100.</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any study drug in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)</title>
          <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) * 100.</description>
          <population>All participants who received any study drug in Part A.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cochran-Armitage trend test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)</title>
        <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)</title>
          <description>ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) * 100.</description>
          <population>All participants who received any study drug in Part B.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
        <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received any study drug in Part A and had DAS28-CRP evaluated at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
          <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
          <population>All randomized participants who received any study drug in Part A and had DAS28-CRP evaluated at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.970"/>
                    <measurement group_id="O2" value="-2.02" spread="1.072"/>
                    <measurement group_id="O3" value="-2.09" spread="1.105"/>
                    <measurement group_id="O4" value="-1.96" spread="0.947"/>
                    <measurement group_id="O5" value="-0.60" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
        <description>DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
        <time_frame>Baseline, 64 weeks</time_frame>
        <population>All randomized participants who received any study drug in Part B and had DAS28-CRP evaluated at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
          <description>DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
          <population>All randomized participants who received any study drug in Part B and had DAS28-CRP evaluated at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="1.152"/>
                    <measurement group_id="O2" value="-2.48" spread="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)</title>
        <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)</title>
          <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
          <population>All participants who received any amount of study drug in Part A.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)</title>
        <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)</title>
          <description>EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and &gt;1.2 improvement from baseline), moderate (absolute: &gt;3.2 and ≤5.1 and &gt;0.6 and ≤1.2 improvement from baseline), or no response (absolute: &gt;5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) * 100.</description>
          <population>All participants who received any amount of study drug in Part B.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part A and had SDAI data at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.</description>
          <population>All participants who received any amount of study drug in Part A and had SDAI data at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.11" spread="8.918"/>
                    <measurement group_id="O2" value="-16.85" spread="9.517"/>
                    <measurement group_id="O3" value="-18.17" spread="9.202"/>
                    <measurement group_id="O4" value="-18.02" spread="8.293"/>
                    <measurement group_id="O5" value="-4.54" spread="13.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in SDAI Responses up to 64 Weeks (Part B)</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.</description>
        <time_frame>Baseline, 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B and had data for SDAI at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in SDAI Responses up to 64 Weeks (Part B)</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.</description>
          <population>All participants who received any amount of study drug in Part B and had data for SDAI at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.42" spread="9.671"/>
                    <measurement group_id="O2" value="-21.33" spread="10.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)</title>
        <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part A and had HAQ-DI evaluated at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)</title>
          <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
          <population>All participants who received any amount of study drug in Part A and had HAQ-DI evaluated at analysis time points. The last non-missing post-baseline value in Part A was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.302" spread="0.3336"/>
                    <measurement group_id="O2" value="-0.396" spread="0.4759"/>
                    <measurement group_id="O3" value="-0.469" spread="0.3463"/>
                    <measurement group_id="O4" value="-0.422" spread="0.3646"/>
                    <measurement group_id="O5" value="-0.077" spread="0.3552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)</title>
        <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
        <time_frame>Baseline, 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B and had HAQ-DI evaluated at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)</title>
          <description>HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.</description>
          <population>All participants who received any amount of study drug in Part B and had HAQ-DI evaluated at analysis time points. The last non-missing post-baseline value in Part B was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.498" spread="0.4779"/>
                    <measurement group_id="O2" value="-0.568" spread="0.6203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of ACR-N Response (Part A)</title>
        <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any study drug in Part A and had baseline and at least one post baseline ACR-N response measure. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) 4 capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of ACR-N Response (Part A)</title>
          <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
          <population>All participants who received any study drug in Part A and had baseline and at least one post baseline ACR-N response measure. LOCF was used to impute missing post-baseline values.</population>
          <units>percentage of responders</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.76" spread="38.65"/>
                    <measurement group_id="O2" value="42.48" spread="39.52"/>
                    <measurement group_id="O3" value="45.17" spread="33.75"/>
                    <measurement group_id="O4" value="25.58" spread="130.02"/>
                    <measurement group_id="O5" value="-9.98" spread="58.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of ACR-N Response (Part B)</title>
        <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any study drug in Part B and had baseline and at least one post baseline ACR-N response measure. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of ACR-N Response (Part B)</title>
          <description>The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of &quot;X&quot; has improvement of at least &quot;X%&quot; in tender and swollen joints and a median improvement of at least &quot;X%&quot; in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.</description>
          <population>All participants who received any study drug in Part B and had baseline and at least one post baseline ACR-N response measure. LOCF was used to impute missing post-baseline values.</population>
          <units>percentage of responders</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.14" spread="30.70"/>
                    <measurement group_id="O2" value="61.07" spread="33.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)</title>
        <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any amount of study treatment in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)</title>
          <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) * 100.</description>
          <population>All participants who received any amount of study treatment in Part A.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)</title>
        <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) * 100.</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)</title>
          <description>DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28−CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36[ln(CRP +1)]+0.014(VAS)+0.96. For remission, DAS28 is &lt;2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) * 100.</description>
          <population>All participants who received any amount of study drug in Part B.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
        <time_frame>Baseline up to 12 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
          <population>All participants who received any amount of study drug in Part A.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)</title>
        <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
        <time_frame>Baseline up to 64 weeks</time_frame>
        <population>All participants who received any amount of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
          </group>
          <group group_id="O2">
            <title>Combined 8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)</title>
          <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:
SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) * 100</description>
          <population>All participants who received any amount of study drug in Part B.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</title>
        <description>Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.</description>
        <time_frame>Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.</time_frame>
        <population>All participants who received any study drug and had evaluable data for AUC(tau,ss).</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</title>
          <description>Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.</description>
          <population>All participants who received any study drug and had evaluable data for AUC(tau,ss).</population>
          <units>nanomoles*hour (nM*h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237" spread="28.8"/>
                    <measurement group_id="O2" value="525" spread="21"/>
                    <measurement group_id="O3" value="1020" spread="32.5"/>
                    <measurement group_id="O4" value="1900" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</title>
        <time_frame>Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.</time_frame>
        <population>All participants who received any study drug and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>4 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>8 mg Baricitinib (LY3009104)</title>
            <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</title>
          <population>All participants who received any study drug and had evaluable Cmax data.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="20.9"/>
                    <measurement group_id="O2" value="73.5" spread="22.5"/>
                    <measurement group_id="O3" value="147" spread="20.6"/>
                    <measurement group_id="O4" value="278" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>1 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>2 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Placebo / 4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E7">
          <title>1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 1 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E8">
          <title>2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 2 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E9">
          <title>4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 4 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E10">
          <title>Placebo /8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered placebo capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E11">
          <title>1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 1 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E12">
          <title>2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 2 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
        <group group_id="E13">
          <title>8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)</title>
          <description>Participants on background methotrexate therapy who were administered 8 mg baricitinib (LY3009104) capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="23" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Birth mark</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thyroiditis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eczema impetiginous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E10" events="15" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="9" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cell marker increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st-t segment abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Endoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lipids abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oesophagogastroduodenoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyposmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Head banging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acne cystic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Drug delivery device implantation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>External fixation of fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal endoscopic therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Internal fixation of fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Open reduction of fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Removal of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

